GEHC

GE HealthCare Technologies Inc. (GEHC) | Rumor.io

GE HealthCare Technologies

GEHC

Attention (50-day avg)0%

Attention rank (50-day avg)#1,533

Bullish sentiment (50-day avg)92%

Price to earnings ratio15.3

Market capitalization30.4B

Earnings per share4.34

Dividend yield (TTM)0.24%

Revenue (annual)20.6B

Net income (annual)2.2B

Social

What share of all stock conversation is about GEHC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 29

GE Healthcare's stock price rose 10% in pre-market trading following its earnings, with revenue reaching $5.3B, beating estimates by $40M, and adjusted EPS of $1.13 beating estimates by 6.6%.
The company reported record organic orders growth of 11.1% and a record backlog, with CEO Peter Arduini attributing the growth to consistent execution across its business segments.
GE Healthcare reaffirmed its full-year guidance, with adjusted EPS expected to be between $4.80-$5.00, matching Wall Street estimates, and organic revenue growth expected to be between 3-4%.

Generated by AI

Sentiment

Of the messages about GEHC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +5	83.87% -14.13	86.22% -2.72
Bearish	—	0% -5	16.13% +14.13	13.78% +2.72

Bullish· Jul 29

The company reported strong order growth of 11% in Q2, driven by broad-based execution across its business segments, and management expressed confidence in the company's performance.
GE HealthCare beat earnings and revenue estimates in Q2, reporting adjusted EPS of $1.13 and $5.295B in revenue, respectively, and reaffirming full-year EPS guidance of $4.80–$5.00.
The stock has broken out of a three-month consolidation pattern and is heading for its highest close since late April, with the CEO citing consistent execution and broad-based growth across the company's business segments.

Bearish· Apr 29

GE HealthCare Technologies Inc. ($GEHC) is expected to face significant increases in memory chip prices, oil, and freight costs, impacting profitability in 2026.
The company's first-quarter adjusted EPS missed estimates by $0.08, and its full-year adjusted EPS guidance was cut to $4.80-$5.00 from $4.95-$5.15 due to inflationary pressures.
GE HealthCare's stock price has declined by over 9% in pre-market trading, with the company's shares also experiencing a 7% drop after-hours, amid concerns over rising supply chain costs and reduced profitability.

Generated by AI

Topics

Of the messages about GEHC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	95.45%	20.69%	56.88%
Earnings	—	0%	25.71%	21%
Macro	—	0%	25.71%	4.94%
Analysts	—	4.55%	26.96%	9.97%
Technical Analysis	—	0%	0.94%	7.04%
Controversies	—	0%	0%	0.16%

Earnings· Jul 29

GE HealthCare reported Q2 earnings with revenue of $5.3B, beating expectations by $40M, and adjusted EPS of $1.13, beating expectations by 8%.
The company reaffirmed its full-year EPS guidance of $4.80-$5.00, matching Wall Street estimates, and organic orders growth of 11.1%, a record quarter.
GE HealthCare's Q2 results were driven by strong services sales, with tariff refunds offsetting a decline in EBIT margins, and the company maintained its FY2026 guidance, including organic revenue growth of 3-4% and adjusted EPS of $4.80-$5.00.

Announcements· Jul 29

GE HealthCare Technologies Inc. reported Q2 2026 earnings with revenue of $5.3B, beating expectations of $5.26B, and organic orders growth of 11.1%, a record quarter.
The company reaffirmed its full-year EPS guidance of $4.80-$5.00 per share, matching Wall Street estimates, and still sees FY organic revenue growth of 3-4%.
GE HealthCare reported strong order growth, with CEO Peter Arduini citing broad-based, consistent execution across its business segments, driven by demand trends across its business segments.

Controversies· Apr 25

China's Ministry of Finance and General Administration of Customs are considering exempting some US goods from tariffs, which could benefit GE HealthCare Technologies Inc. ($GEHC).
The move is seen as a response to the areas of China's economy that remain reliant on US goods, including medical equipment made by US firms like GE Healthcare.
Exempting tariffs on medical equipment could have a positive impact on GE HealthCare Technologies Inc. ($GEHC) amid ongoing trade tensions between the US and China.

Macro· Apr 25

China may exempt some US goods, including medical equipment made by GE HealthCare, from tariffs as costs rise.
China's move may be seen as damage control rather than a peace offering, and could benefit GE HealthCare amidst ongoing trade tensions.
GE HealthCare's sales in China fell 15% in 2024, and the company expects pressure in the short term, despite potential benefits from China's tariff suspension.

Generated by AI

Community

Of the messages about GEHC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	10.87%	45.97%	29.2%
Newcomers	—	89.13%	54.03%	70.8%

Regulars· Jul 29

GE HealthCare Technologies Inc. reported Q2 2026 earnings, with revenue of $5.3B, a 5.7% YoY increase, and adjusted EPS of $1.13, a 6.6% YoY increase, beating estimates.
The company reaffirmed its full-year EPS guidance of $4.80-$5.00, matching Wall Street estimates, and still sees FY organic revenue growth of 3-4%.
GEHC's Q2 orders growth of 11.1% was driven by broad-based, consistent execution across its product lines, and the company's stock jumped 12.2% on the earnings news, breaking out of a three-month consolidation pattern.

Newcomers· Jul 29

Newcomers are focusing on GE HealthCare's strong Q2 earnings, with revenue beating expectations and adjusted EPS of $1.13, a 6.6% YoY increase.
The company has reported record organic orders growth of 11.1% and a record order backlog of $23.9B, with management expressing confidence in demand trends across its business segments.
Despite the Patient Care Solutions segment experiencing a decline in revenue and EBIT margin, the company has reaffirmed its full-year guidance and is exploring strategic options for this segment.

Generated by AI

News

Veteran Needham analyst sees 44% upside in tumbling health stock

4d agothestreet.com

GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over?

6d agoYahoo Finance

GE HealthCare announces cash dividend increase for third quarter of 2026

7d agoYahoo Finance

GE HealthCare Technologies Inc. stock rises Tuesday, outperforms market

7d agoMarketWatch

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

CHICAGO, September 22, 2026--GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformation.

7d agoYahoo Finance

GEHC Could Be Set For A Turnaround — Needham Sees 44% Upside For GE Healthcare After Nearly 21% YTD Slide

Needham initiated coverage with a ‘Buy’ rating and $93 price target, putting GEHC among the stocks it expects to outperform.

7d agoYahoo Finance

Also Discussed

Investors talking about GEHC also mention

#	Name	Attention
1	First Trust Dividend Strength ETFFTDS	0%0
2	Enlivex Ltd.ENLV	0%new
3	Global X Nasdaq 100 Covered Call & Growth ETFQYLG	0%new
4	Invesco BulletShares 2031 High Yield Corporate Bond ETFBSJV	0%0
5	Arch Capital Group Ltd.ACGL	0%0
6	Huntington Bancshares Incorporated Common StockHBAN	0%0
7	Direxion Daily NFLX Bull 2X ETFNFXL	0%new
8	Formula Systems (1985) Ltd. American Depositary SharesFORTY	0%0
9	Transcontinental Realty Investors, Inc.TCI	0%0
10	Twin Vee PowerCats Co. Common StockVEEE	0%new

GE HealthCare Technologies Inc.

Healthcare
Medical Devices

GE HealthCare Technologies Inc. is a global medical technology and diagnostics company that develops imaging systems, ultrasound equipment, patient monitoring and anesthesia solutions, and pharmaceutical diagnostics products. Its portfolio supports hospitals, health systems, and clinical providers with tools used in diagnosis, treatment, and patient care across routine and complex medical settings. GE HealthCare also offers software, digital workflows, and service capabilities that help healthcare organizations manage equipment, improve clinical efficiency, and integrate data across care environments. The company’s main business areas include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, reflecting its broad role in modern healthcare infrastructure. Headquartered in Chicago, Illinois, GE HealthCare focuses on technologies and services that are widely used in medical imaging, bedside monitoring, and diagnostic procedures worldwide.

Website

Location

500 West Monroe Street

Chicago, IL, 60661

United States

Social

What share of all stock conversation is about GEHC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 29

GE Healthcare's stock price rose 10% in pre-market trading following its earnings, with revenue reaching $5.3B, beating estimates by $40M, and adjusted EPS of $1.13 beating estimates by 6.6%.
The company reported record organic orders growth of 11.1% and a record backlog, with CEO Peter Arduini attributing the growth to consistent execution across its business segments.
GE Healthcare reaffirmed its full-year guidance, with adjusted EPS expected to be between $4.80-$5.00, matching Wall Street estimates, and organic revenue growth expected to be between 3-4%.

Generated by AI

Sentiment

Of the messages about GEHC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +5	83.87% -14.13	86.22% -2.72
Bearish	—	0% -5	16.13% +14.13	13.78% +2.72

Bullish· Jul 29

The company reported strong order growth of 11% in Q2, driven by broad-based execution across its business segments, and management expressed confidence in the company's performance.
GE HealthCare beat earnings and revenue estimates in Q2, reporting adjusted EPS of $1.13 and $5.295B in revenue, respectively, and reaffirming full-year EPS guidance of $4.80–$5.00.
The stock has broken out of a three-month consolidation pattern and is heading for its highest close since late April, with the CEO citing consistent execution and broad-based growth across the company's business segments.

Bearish· Apr 29

GE HealthCare Technologies Inc. ($GEHC) is expected to face significant increases in memory chip prices, oil, and freight costs, impacting profitability in 2026.
The company's first-quarter adjusted EPS missed estimates by $0.08, and its full-year adjusted EPS guidance was cut to $4.80-$5.00 from $4.95-$5.15 due to inflationary pressures.
GE HealthCare's stock price has declined by over 9% in pre-market trading, with the company's shares also experiencing a 7% drop after-hours, amid concerns over rising supply chain costs and reduced profitability.

Generated by AI

Topics

Of the messages about GEHC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	95.45%	20.69%	56.88%
Earnings	—	0%	25.71%	21%
Macro	—	0%	25.71%	4.94%
Analysts	—	4.55%	26.96%	9.97%
Technical Analysis	—	0%	0.94%	7.04%
Controversies	—	0%	0%	0.16%

Earnings· Jul 29

GE HealthCare reported Q2 earnings with revenue of $5.3B, beating expectations by $40M, and adjusted EPS of $1.13, beating expectations by 8%.
The company reaffirmed its full-year EPS guidance of $4.80-$5.00, matching Wall Street estimates, and organic orders growth of 11.1%, a record quarter.
GE HealthCare's Q2 results were driven by strong services sales, with tariff refunds offsetting a decline in EBIT margins, and the company maintained its FY2026 guidance, including organic revenue growth of 3-4% and adjusted EPS of $4.80-$5.00.

Announcements· Jul 29

GE HealthCare Technologies Inc. reported Q2 2026 earnings with revenue of $5.3B, beating expectations of $5.26B, and organic orders growth of 11.1%, a record quarter.
The company reaffirmed its full-year EPS guidance of $4.80-$5.00 per share, matching Wall Street estimates, and still sees FY organic revenue growth of 3-4%.
GE HealthCare reported strong order growth, with CEO Peter Arduini citing broad-based, consistent execution across its business segments, driven by demand trends across its business segments.

Controversies· Apr 25

China's Ministry of Finance and General Administration of Customs are considering exempting some US goods from tariffs, which could benefit GE HealthCare Technologies Inc. ($GEHC).
The move is seen as a response to the areas of China's economy that remain reliant on US goods, including medical equipment made by US firms like GE Healthcare.
Exempting tariffs on medical equipment could have a positive impact on GE HealthCare Technologies Inc. ($GEHC) amid ongoing trade tensions between the US and China.

Macro· Apr 25

China may exempt some US goods, including medical equipment made by GE HealthCare, from tariffs as costs rise.
China's move may be seen as damage control rather than a peace offering, and could benefit GE HealthCare amidst ongoing trade tensions.
GE HealthCare's sales in China fell 15% in 2024, and the company expects pressure in the short term, despite potential benefits from China's tariff suspension.

Generated by AI

Community

Of the messages about GEHC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	10.87%	45.97%	29.2%
Newcomers	—	89.13%	54.03%	70.8%

Regulars· Jul 29

GE HealthCare Technologies Inc. reported Q2 2026 earnings, with revenue of $5.3B, a 5.7% YoY increase, and adjusted EPS of $1.13, a 6.6% YoY increase, beating estimates.
The company reaffirmed its full-year EPS guidance of $4.80-$5.00, matching Wall Street estimates, and still sees FY organic revenue growth of 3-4%.
GEHC's Q2 orders growth of 11.1% was driven by broad-based, consistent execution across its product lines, and the company's stock jumped 12.2% on the earnings news, breaking out of a three-month consolidation pattern.

Newcomers· Jul 29

Newcomers are focusing on GE HealthCare's strong Q2 earnings, with revenue beating expectations and adjusted EPS of $1.13, a 6.6% YoY increase.
The company has reported record organic orders growth of 11.1% and a record order backlog of $23.9B, with management expressing confidence in demand trends across its business segments.
Despite the Patient Care Solutions segment experiencing a decline in revenue and EBIT margin, the company has reaffirmed its full-year guidance and is exploring strategic options for this segment.

Generated by AI

GE HealthCare Technologies

Social

Jul 29

Bullish· Jul 29

Bearish· Apr 29

Earnings· Jul 29

Announcements· Jul 29

Controversies· Apr 25

Macro· Apr 25

Regulars· Jul 29

Newcomers· Jul 29

Veteran Needham analyst sees 44% upside in tumbling health stock

GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over?

GE HealthCare announces cash dividend increase for third quarter of 2026

GE HealthCare Technologies Inc. stock rises Tuesday, outperforms market

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

GEHC Could Be Set For A Turnaround — Needham Sees 44% Upside For GE Healthcare After Nearly 21% YTD Slide

Also Discussed

GE HealthCare Technologies Inc.

Company Information

Location

Veteran Needham analyst sees 44% upside in tumbling health stock

GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over?

GE HealthCare announces cash dividend increase for third quarter of 2026

GE HealthCare Technologies Inc. stock rises Tuesday, outperforms market

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

GEHC Could Be Set For A Turnaround — Needham Sees 44% Upside For GE Healthcare After Nearly 21% YTD Slide

Also Discussed

Social

Jul 29

Bullish· Jul 29

Bearish· Apr 29

Earnings· Jul 29

Announcements· Jul 29

Controversies· Apr 25

Macro· Apr 25

Regulars· Jul 29

Newcomers· Jul 29